Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

pembrolizumab 8Nivolumab 3tislelizumab 2spartalizumab 2SS1(dsFv)PE38 2Ipilimumab 2fludarabine phosphate 1fludarabine 1epacadostat 1entinostat 1bosutinib 1atezolizumab 1aldesleukin 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Microarray Analysis 1Interleukin-2 1Immunotherapy 1Immunoenzyme Techniques 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Gemcitabine 1Flow Cytometry 1Fentanyl 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × BAY 1895344 × Other solid neoplasm × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡